SCHEMBL6315910

SCHEMBL6315910

CC(C)(C)OC(=O)C(Cc1ccccc1)Nc1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.54
CYP2C8 P10632 1/20 0.54
CYP2C9 P11712 1/20 0.54
NPR3 P17342 1/20 0.54
CYP2C19 P33261 1/20 0.54
ITGA4 P13612 2/20 0.53
ITGB7 P26010 2/20 0.53
FPR2 P25090 2/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 5/20 0.49
TDP1 Q9NUW8 4/20 0.49
CTSS P25774 3/20 0.49
CTSK P43235 2/20 0.49
POLB P06746 2/20 0.49
MMP1 P03956 1/20 0.48
MMP3 P08254 1/20 0.48
MMP9 P14780 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14902624 0.85 FPR2 (0.70) FPR2MEN1KMT2ANPC1RAB9A
SCHEMBL28348563 0.85 FPR2 (0.70) FPR2MEN1KMT2ANPC1RAB9A
SCHEMBL5887302 0.84 ITGA4 (0.64) ITGA4ITGB7FPR2MEN1KMT2A
SCHEMBL5887295 0.84 ITGA4 (0.64) ITGA4ITGB7FPR2MEN1KMT2A
SCHEMBL17542476 0.83 ITGA4 (0.64) CYP3A4CYP2C8CYP2C9NPR3CYP2C19
SCHEMBL30437754 0.82 NPR3 (0.55) CYP3A4CYP2C8CYP2C9NPR3CYP2C19
SCHEMBL5887598 0.81 P2RX7 (0.59) MAPTTDP1CTSSCTSKPOLB
SCHEMBL5887595 0.81 P2RX7 (0.59) MAPTTDP1CTSSCTSKPOLB
SCHEMBL8445738 0.81 CTSL (0.67) ITGA4ITGB7MEN1KMT2AMAPT
SCHEMBL13020623 0.79 ITGA4 (0.61) CYP3A4CYP2C8CYP2C9NPR3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US disclosed
EP-1395571-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Shire Biochem Inc. (CA) 2004-03-10 EP disclosed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US disclosed
WO-2002100846-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SHIRE BIOCHEM INC. (CA) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections HAVCR2, ZC3HAV1, MAVS CYP3A4 452/4885CYP2C8 451/4885CYP2C9 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.